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Abstracts / Urological Science 27 (2016) S24eS35S26acinar proliferation as well as prostatic intraepithelial neoplasia. 14 (36.8%)
patients in ASAP group were later diagnosed as prostate cancer, 6 (23.1%)
patients in PIN group were later diagnosed as prostate cancer, and 100%
patients in ASAP+PIN group were later diagnosed as prostate cancer.
Conclusion: Patients with a diagnosis of ASAP or extensive high grade PIN
during prostate biopsy had a higher chance of developing prostate cancer,
especially for patients with a simultaneous diagnosis of ASAP + PIN in the
same biopsy. These patients should receive second time biopsy during
follow up. Most cancer of the cancer in these patients could be detected
within twice re-biopsy.
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Purpose: AR-V7 is one of a splicing variant of the Androgen receptor (AR).
It cause castration resistant prostate cancer (CRPC).
Incontrast, CTCs is expected as a predictive factor for patient's prognosis
and as a biomarker of the disease.
CellSearch is the only FDA approval method as an evaluation of CTCs
ensuring the quantitative evaluation. This methodology is depending on
the expression of EpCAM and CK. However, the decrease expression of
EpCAM and CK caused by Epithelial-Mesenchymal Transition (EMT) can be
an obstacle to CTC detection.
In recent years, AdnaTest is used for the evaluation of CRPC. It captures CTC
depending on EpCAM and Her2 expression on cancer cells, then assess the
presence of AR-V7 mRNA. But, this method is semi-quantitative and also
depending on expression of EpCAM.
We consider it is important to know the number of ARV-7 positive cells
accurately. Because, CTCs of each prostate cancer patients are
heterogeneous.
The aim of our study is to establish a new method of improved detection
rate of EpCAM and CK-negative cells (i.e EMTcells), ensure the quantitative
evaluation and assess the number of AR-V7-positive cells.
Materials and Methods: LNcap was used as hormone sensitive prostate
cancer (HSPC) model, and Vcap, PC3 and Du145 were used as CRPC model.
Peripheral blood mononuclear cell (PBMC) and VMRC-RCW (Renal cell
carcinoma cell) were used as negative control.
CK and EpCAM antibodies were used as CTC-speciﬁc antibodies.PSA, PSMA
and AR-FL antibody were used as prostate-speciﬁc antibodies, cells which
show positivitiys for those antiodies within peripheral blood were
considered as CTCs.In addition, vimentin antibody was used for the pur-
pose of evaluating the EMT cells.
AR-V7 antibody was used as a biomarker for prostate cancer. On-chip sort
was used for quantitative assessment of CTCs.
Conclusion: Negativity of CK-Ab for LNCap and EpCAM-Ab for PC3 may
indicate that EMToccurs in LNCap and PC3. Positivity of PSMA-Ab, PSA-Ab
and AR-FL-Ab for LNCap indicates the possibility of improving the
detection rate of CTC. Positivity of AR-V7-Ab for Vcap and low positivity
for LNcap were likely to be the evaluation of new biomarkers in CTC
studies.
IPD09:
THE IMPACT OF TUMOR LOCATIONS ON LOCAL RECURRENCES IN
PROSTATE CANCER PATIENTS RECEIVING CRYOABLATION
Shih-Chun Hung, Chung-Hsin Chen, Yeong-Shiau Pu. Department of
Urology, National Taiwan University Hospital, National Taiwan University
College of Medicine, Taipei, Taiwan
Purpose: To evaluate the impact of tumor locations on local recurrences in
prostate cancer patient who received cryoablation
Materials and Methods: A total 255 patients with prostate cancer who
received primary cryoablation in National Taiwan University Hospital be-
tween January 2008 and December 2012 were enrolled. During follow-up,biochemical failure (Phoenix criteria) would trigger prostate biopsies.
Local recurrence refers to pathologically proven prostate cancer in prostate
and seminal vesicles. The prostate was deﬁned into eight areas: left lateral
(LL), left medial (LM), left apex (LA), right lateral (RL), right medial (RM),
right apex (RA), anterior and midline posterior (PM). The seminal vesicles
also deﬁned as one area each: left seminal vesicle (LSV), right seminal
vesicle (RSV). We analyzed the prostate cancer recurrence rate of each area
after primary cryoablation.
Results: A total of 46 (18.0%) patients had local recurrences during a me-
dian follow-up duration of 5 years. In the primary tumor areas, local
recurrence rates were 7.1% (RM), 3.4% (RA), 2.4% (RSV), 2.6% (LSV), 1.1%
(LM), 2.1% (LL), and 0 (RL, anterior, PM, LA). For the areas with negative
results for malignancy in pre-operative prostate biopsies, local recurrence
rates were 2.4% (RSV), 1.1% (RL) and 0 (other areas). For patients whose
anterior and PM areas were not routinely examed in pre-operative prostate
biopsy, local recurrence rates were 3.3% (anterior) and 1.7% (PM). Multi-
variate analysis revealed higher tumor stages, and tumor locations at RM,
and anterior areas were associated with higher risk of local recurrence.
Those patients with previously proved cancer distribution at the right
medial had highest recurrence rate at this area.
Conclusion: Limited to the nature of cryoablation and preservation of vital
organs nearby, tumor locations in prostate would interfere with the suc-
cessful rate of prostate cryoablation. To improve oncological outcomes,
detailed and accurate tumor locations is essential for prostate patients
who plan to receive cryoablation.
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Purpose: We investigated the treatment outcome of testicular cancer in
Taiwan, given globally rise in incidence in recent decades.
Materials and Methods: From February 2010 to October 2015, we retro-
spectively collected patients with the conﬁrmed diagnosis of testicular
cancer. Clinical data, pathological details and treatment outcomes were
analyzed by reviewing medical records.
Results: A total of 81 patients with testicular cancer were enrolled; 40
(49.4%) had seminoma and 41(50.6%) had non-seminoma germ cell cancer.
The median age was 51 years old in seminoma and 30 years old in non-
seminoma group. The median follow up period was 30 months (range 1 to
70).
The staging in seminoma group showed 36 (90%) stage I, 1 (2.5%) stage IS, 2
(5%) stage II and 1 (2.5%) stage III. The staging in non-seminoma group was
29 (70%) stage I, 4 (10%) stage IS, 3 (7%) stage II and 5 (12%) stage III.
Approximately 97% of patients (35/36) with stage I seminoma and 90% (26/
29) of patients with stage I non-seminoma accepted active surveillance.
The overall recurrence rates were 12.5 % in seminoma and 31.7% in non-
seminoma group. Only two patients in Non-seminoma group died of
cancer. The 5-year recurrence free survival was 94.2% in seminoma and
84.2% in non-seminoma group. Five year overall survival yielded favorable
results: 100% in seminoma and 94.2% in non-seminoma group.
Conclusion: Our study provided the latest evidence on oncological out-
comes of testicular cancer. Active Surveillance in stage I testicular cancer
yielded good prognosis and served as a treatment option.
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Purpose: Ketamine is the most commonly abused psychotropic substance
among youngsters in Taiwan. Long-term ketamine use can cause chronic
